San Diego Biotech

Biotech Directory

Dec
22

UPDATED: J&J steps up with $700M deal for MacroGenics’ blood cancer drug, shares spike

Posted under Blog, Companies, Diagnostics, Funding, Johnson & Johnson, MacroGenics, Medical Devices, Medical Supply, Partnering, Pharmaceuticals, Startups, Universities, Videos by John Carroll

Johnson & Johnson is fronting $125 million to gain the worldwide license on a bispecific cancer drug from MacroGenics, with up to $575 million more promised in prospective milestones for a successful development program. And the biotech says that the deal marks the beginning of a new program for a drug designed to stir a T cell attack against blood cancers.

Dec
22

UPDATED: Achillion shares surge as hep C drug scores a quick 6-week cure

Posted under Achillion, Blog, Clinical Trials, Companies, Diagnostics, Funding, Medical Devices, Medical Supply, Pharmaceuticals, Startups, Universities, Videos by John Carroll

Shares of Achillion rocketed up Monday morning after the biotech reported that its NS5A drug combined with Gilead's Sovaldi scored a quick cure among a small group of hepatitis C patients after only 6 weeks of treatment. Meanwhile, its nucleotide inhibitor ACH-3422 was a success in a tiny proof-of-concept Phase I study, raising the likelihood that Achillion has its own in-house combo that can compete with the heavyweights on the market. And the news is likely to renew speculation of a possible buyout as a second wave of drug developers looks to compete with Gilead and new arrival AbbVie.

Dec
19

UPDATED: AbbVie wins blockbuster hep C approval, starts wheeling and dealing on price

Posted under AbbVie, Blog, Companies, Diagnostics, Funding, Hepatitis C, Medical Devices, Medical Supply, Pharmaceuticals, Regulatory, Startups, Universities, Videos by Damian Garde

AbbVie won an expected FDA approval for its next-generation treatment for hepatitis C, kicking off a race with Gilead Sciences for dominance in a blockbuster field.

Dec
19

AstraZeneca grabs a surprise early approval for its $2B cancer contender

Posted under AstraZeneca, Blog, Companies, Diagnostics, Funding, Medical Devices, Medical Supply, olaparib, Pharmaceuticals, Pipeline, Regulatory, Startups, Universities, Videos by Damian Garde

Despite loud objections from its advisers, the FDA granted an accelerated approval to AstraZeneca's ovarian cancer treatment, clearing an oral therapy the U.K. drugmaker believes will bring in blockbuster sales.